326 related articles for article (PubMed ID: 34913594)
21. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C.
Osuch S; Laskus T; Berak H; Perlejewski K; Metzner KJ; Paciorek M; Radkowski M; Caraballo Cortés K
Sci Rep; 2020 Sep; 10(1):16060. PubMed ID: 32994477
[TBL] [Abstract][Full Text] [Related]
22. Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia.
Liang C; Zhao Y; Chen C; Huang S; Deng T; Zeng X; Tan J; Zha X; Chen S; Li Y
Front Oncol; 2021; 11():740642. PubMed ID: 34692519
[TBL] [Abstract][Full Text] [Related]
23. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
24. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.
Schnorfeil FM; Lichtenegger FS; Emmerig K; Schlueter M; Neitz JS; Draenert R; Hiddemann W; Subklewe M
J Hematol Oncol; 2015 Jul; 8():93. PubMed ID: 26219463
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of aberrant PD-1 expression for acute leukemia prognosis.
Ruan Y; Wang J; Zhang Q; Wang H; Li C; Xu X; Zhai Z
Eur J Med Res; 2023 Sep; 28(1):383. PubMed ID: 37759316
[TBL] [Abstract][Full Text] [Related]
26. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
27. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
[No Abstract] [Full Text] [Related]
28. Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients.
Batorov EV; Aristova TA; Sergeevicheva VV; Sizikova SA; Ushakova GY; Pronkina NV; Shishkova IV; Shevela EY; Ostanin AA; Chernykh ER
Sci Rep; 2020 Nov; 10(1):20846. PubMed ID: 33257767
[TBL] [Abstract][Full Text] [Related]
29. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.
Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M
J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915
[TBL] [Abstract][Full Text] [Related]
30. Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms.
Hu H; Zhao J; Yuan J; Zhang M
BMC Cancer; 2023 Mar; 23(1):287. PubMed ID: 36991376
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
Noviello M; Manfredi F; Ruggiero E; Perini T; Oliveira G; Cortesi F; De Simone P; Toffalori C; Gambacorta V; Greco R; Peccatori J; Casucci M; Casorati G; Dellabona P; Onozawa M; Teshima T; Griffioen M; Halkes CJM; Falkenburg JHF; Stölzel F; Altmann H; Bornhäuser M; Waterhouse M; Zeiser R; Finke J; Cieri N; Bondanza A; Vago L; Ciceri F; Bonini C
Nat Commun; 2019 Mar; 10(1):1065. PubMed ID: 30911002
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
34. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function.
Raziorrouh B; Schraut W; Gerlach T; Nowack D; Grüner NH; Ulsenheimer A; Zachoval R; Wächtler M; Spannagl M; Haas J; Diepolder HM; Jung MC
Hepatology; 2010 Dec; 52(6):1934-47. PubMed ID: 21064032
[TBL] [Abstract][Full Text] [Related]
35. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
36. Double Positive CD4
Kochanowicz AM; Osuch S; Berak H; Kumorek A; Caraballo Cortés K
Cells; 2023 May; 12(10):. PubMed ID: 37408280
[TBL] [Abstract][Full Text] [Related]
37. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
38. Splenic CD4
Huang N; Zhou R; Chen H; Zhang S; Li J; Wei W; Sun J; Ren S; Li B; Deng H; Yang J; Ji F; Li Z
Int J Immunopathol Pharmacol; 2021; 35():20587384211061051. PubMed ID: 34930041
[No Abstract] [Full Text] [Related]
39. [The expression and correlation analysis of TOX and inhibitory receptors on peripheral blood CD8
Yan L; Yang JR; Wang HQ; Shao ZH
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2095-2099. PubMed ID: 37455127
[No Abstract] [Full Text] [Related]
40. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
